VentureMed Group receives FDA 510(k) clearance for FLEX Scoring Catheter

NewsGuard 100/100 Score

VentureMed Group, Ltd., a medical device company based in northwest Ohio, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the commercial distribution of a new surgical device for treating peripheral artery disease (PAD). It's called the FLEX Scoring Catheter® and was developed by ProMedica Vascular Surgeon John Pigott, MD, as an alternative to balloon-based scoring with a one-size-fits-all platform technology. Dr. Pigott founded VentureMed Group, which specializes in the development and commercialization of innovative and cost-effective endovascular medical devices.

FLEX, which received CE Mark in Europe in 2015, provides interventionalists with a device that allows them to care for patients with severely blocked arteries that might not be effectively treated with traditional balloon procedures.

"Using FLEX prior to balloon angioplasty in our first-in-man trial, we were able to show statistically significant improvement in ankle-brachial index scores at 30 days," said Dr. Pigott, chief science officer, VentureMed Group, Ltd. "Benefits for PAD patients may include fewer dissections and improved results at procedure completion. In fact, we continue to see encouraging data from early adopters across the European Union."

How the FLEX Scoring Catheter works
The FLEX Scoring Catheter surgical device is inserted through the patient's artery to a point just below the blockage. The surgeon pulls a thumb lever that exposes three precision micro-blades that are mounted at the tip of the catheter. As the catheter is drawn through the plaque, the micro-blades make continuous scores, relaxing the plaque. Next, an angioplasty balloon is inflated to open up the artery, allowing blood to flow freely.

"FLEX deploys quickly and is easy to use, saving the interventionalist procedural time," said Gary Smith, chief executive officer, VentureMed Group, Ltd. "Priced at a third of the cost of similar devices, it is an excellent vessel preparation tool for use with balloon angioplasty."

What is PAD?
Approximately 12 million people in the United States have PAD, the narrowing or blockage of the vessels that carry blood from the heart to the legs. PAD is usually caused by a buildup of plaque in the vessels and results in leg pain, difficultly walking, numbness or weakness in the legs. Left untreated, it could lead to amputation, heart attack and stroke.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Treating gum disease during AFib blanking period could reduce recurrence risk